InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,320.06
(
-0.03%
)
US TECH 100
18,250.00
(
0.10%
)
Dow Jones
39,864.30
(
-0.02%
)
Brent Oil
81.62
(
-1.00%
)
Bitcoin
69,507.98
(
-0.89%
)
Post# of 251889
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 188348

Sunday, 03/08/2015 6:25:54 PM

Sunday, March 08, 2015 6:25:54 PM

Post# of 251889
I don't recall NVS gave the actual sales figures of individual products but it stated few time about the success of Zarzio in Europe. For example:

"Sandoz G-CSF biosimilar, Zarzio, continued to strengthen its leading position as the number one filgrastim product in Europe by volume, ahead of Amgen’s Neupogen® and Chugai’s Granocyte®."

http://www.novartis.com/downloads/newsroom/corporate-fact-sheet/4a_Sandoz_EN.pdf

Or this one:

"ZARZIO is the number one biosimilar filgrastim globally and is the leading daily G-CSF in Europe with 30 percent volume market share."

http://www.novartis.com/newsroom/media-releases/en/2014/1835571.shtml
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up